NDC 71335-2456 – Celecoxib
Celecoxib 200 mg/1 · Capsule · Oral
Product NDC71335-2456
Product details
- Brand name
- Celecoxib
- Generic name
- Celecoxib
- Labeler
- Bryant Ranch Prepack
- Dosage form
- Capsule
- Route
- Oral
- Marketing category
- ANDA · ANDA210071
- Marketed since
- December 21, 2020
- Listing expires
- December 31, 2026
- Pharmacologic class
- Nonsteroidal Anti-inflammatory Drug
Active ingredients
- Celecoxib 200 mg/1
Package NDC codes (10)
| Package NDC | Description | Since |
|---|---|---|
| 71335-2456-0 | 15 CAPSULE in 1 BOTTLE (71335-2456-0) | Feb 3, 2025 |
| 71335-2456-1 | 30 CAPSULE in 1 BOTTLE (71335-2456-1) | Aug 2, 2024 |
| 71335-2456-2 | 60 CAPSULE in 1 BOTTLE (71335-2456-2) | Jul 31, 2024 |
| 71335-2456-3 | 90 CAPSULE in 1 BOTTLE (71335-2456-3) | Feb 3, 2025 |
| 71335-2456-4 | 14 CAPSULE in 1 BOTTLE (71335-2456-4) | Aug 2, 2024 |
| 71335-2456-5 | 20 CAPSULE in 1 BOTTLE (71335-2456-5) | Feb 3, 2025 |
| 71335-2456-6 | 10 CAPSULE in 1 BOTTLE (71335-2456-6) | Feb 3, 2025 |
| 71335-2456-7 | 180 CAPSULE in 1 BOTTLE (71335-2456-7) | Feb 3, 2025 |
| 71335-2456-8 | 28 CAPSULE in 1 BOTTLE (71335-2456-8) | Feb 3, 2025 |
| 71335-2456-9 | 56 CAPSULE in 1 BOTTLE (71335-2456-9) | Feb 3, 2025 |
Other Celecoxib products
- 50090-6758 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-5178 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6577 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-5638 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-7072 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6759 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-8036 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 50090-8031 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 50090-4789 Celecoxib 200 mg/1 · Capsule · A-S Medication Solutions
- 50090-6380 Celecoxib 100 mg/1 · Capsule · A-S Medication Solutions
- 0591-3983 Celecoxib 100 mg/1 · Capsule · Actavis Pharma, Inc.
- 0591-3984 Celecoxib 200 mg/1 · Capsule · Actavis Pharma, Inc.